Tucaliv™ 150 Tablets Tucaliv™ 150 Tablets contain Tucatinib, a selective HER2 tyrosine kinase inhibitor used in combination with trastuzumab and capecitabine for the treatment of HER2-positive unresectable or metastatic breast cancer. It works by blocking HER2 signaling, helping slow the growth and spread of cancer cells, including in patients with brain metastases.

Effects & Benefits Specifically targets HER2-positive cancer cells. Helps slow tumor growth and disease progression. Used for HER2-positive metastatic or unresectable breast cancer. Effective in patients with brain metastases when used in combination therapy. Helps improve progression-free survival. Oral tablet for convenient long-term treatment under specialist supervision.